citicoline
Small moleculeexperimental
Citicoline (INN), also known as cytidine diphosphate-choline (CDP-choline) or cytidine 5'-diphosphocholine is an intermediate in the generation of phosphatidylcholine from choline, a common biochemical process in cell membranes. Citicoline is naturally occurring in the cells of human and animal tissue, in particular the organs. — Wikipedia
Clinical trial activity
52 trials · 60 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
22
Phase 3
13
Phase 4
8
Earliest trial started Feb 1, 2005 (NCT00404729)
Timeline
Indications
Approved for
Studied for
- Air Travel · Phase 2/Phase 3
- Alcoholism · Phase 4
- Bipolar Disorder · Phase 4
- Brain Injuries · Phase 2
- Brain Injuries, Traumatic · Phase 3
- Cerebral Infarction · Phase 4
- Cocaine-Related Disorders · Phase 4
- Cognition Disorders · Phase 2
- COVID-19 · Phase 1/Phase 2
- Delirium · Phase 4
- Diabetic Retinopathy · Phase 1
- Fragile X Syndrome · Phase 2
- Glaucoma · Phase 4
- Glaucoma, Open-Angle · Phase 3
- Hypoxia-Ischemia, Brain · Phase 3
- Infant, Premature · Phase 3
- Intensive Care Units · Phase 4
- Ischemic Stroke · Phase 3
- Mania · Phase 3
- Marijuana Abuse · Phase 2
- Methamphetamine · Phase 3
- Neonatology · Phase 3
- Neural Conduction · Phase 4
- Neuroprotection · Phase 3
- Optic Nerve · Phase 4
- Optic Neuropathy, Ischemic · Phase 4
- Schizophrenia · Phase 4
- Stroke · Phase 3
- Substance-Related Disorders · Phase 2
- Visual Pathways · Phase 4
Mechanism of action
- cholineSupplementation
choline supplementation
Chemistry & pharmacology
Loading structure…
SMILES
C[N+](C)(C)CCOP(=O)(O)OP(=O)(O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=CC(=NC2=O)N- Mol. weight
- 489.34 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1618340 ↗
- WikipediaCiticoline ↗
- ChEMBLCHEMBL1256994 ↗
- ChEMBLCHEMBL1231700 ↗
Also known as
- cdp-cholin
- cdp-cholin
- cdp-choline
- cdp-choline
- ceraxon
- ceraxon
- choline cytidine diphosphate
- citicholine
- citicoline
- citicoline
- citicoline
- citicoline
- citicoline
- citicoline
- citicoline
- citicoline
- citicoline sodium
- citicoline sodium
- citidoline
- corenalin
- cyscholin
- cytidine-5'-diphosphocholine
- cytidine-5'-diphosphocholine
- cytidine choline diphosphate
- cytidine diphosphate choline
- cytidine diphosphocholine
- cytidine diphosphorylcholine
- cytidoline
- difosfocin
- emicholine
- ip-302-sodium
- ip-302-sodium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07089238 | N/A | Jul 31, 2025 | Kyowa Kirin, The Center for Applied Health Sciences, LLC |
| NCT06906848 | N/A | Nov 20, 2024 | Kyowa Kirin, Nutrasource Diagnostics |
| NCT05870111 | Phase 2 | Feb 29, 2024 | Medical University of South Carolina |
| NCT06431113 | Phase 3 | Jan 27, 2024 | University of Naples Frederico II, University of Pavia, University of Roma La Sapienza |
| NCT06029894 | N/A | Dec 16, 2023 | Emory University, National Institute on Aging (NIA) |
| NCT05881135 | Phase 1/Phase 2 (Phase 2) | Jun 6, 2023 | Ohio State University |
| NCT05710198 | Phase 3 | Apr 1, 2023 | Omikron Italia S.r.l. |
| NCT06210646 | Phase 3 | Dec 29, 2022 | Kafrelsheikh University |
| NCT05200208 | N/A | Jul 27, 2022 | Emory University, National Institute on Aging (NIA) |
| NCT05315206 | N/A | Jan 25, 2022 | Fondazione G.B. Bietti, IRCCS |
| NCT04967157 | N/A | Sep 8, 2021 | Biofortis, Kyowa Kirin |
| NCT05154903 | Phase 3 | Jul 22, 2021 | Ain Shams University, Kafrelsheikh University |
| NCT04802785 | Phase 2/Phase 3 (Phase 3) | Jun 30, 2021 | lurye Clinic |
| NCT04499157 | N/A | Aug 31, 2020 | University of Picardie Jules Verne |
| NCT03966170 | Phase 3 | May 1, 2019 | Kafrelsheikh University, Tanta University |
| NCT03949049 | Phase 3 | Feb 1, 2019 | Kafrelsheikh University, Tanta University |
| NCT03444662 | N/A | Jun 12, 2018 | Kyowa Hakko Kogyo, Oregon Health and Science University |
| NCT04003090 | N/A | Mar 21, 2018 | Fondazione G.B. Bietti, IRCCS, Istituto di Ricerca Neuroftalmologia S.r.l. |
| NCT04422743 | Phase 2 | Jan 25, 2018 | Foundation IRCCS San Matteo Hospital, University of Pavia |
| NCT03369925 | N/A | Jan 2, 2018 | Biofortis, Kyowa Hakko Kogyo |
Showing 20 of 52 trials
Page 1 / 3
Organizations
Research & Development (60)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| The University of Texas, Dallas | Academic/Hospital | 7 | 6 | 3 | 2006 |
| Fondazione G.B. Bietti, IRCCS | Academic/Hospital | 5 | 4 | 2 | 2005 |
| Kafrelsheikh University | Academic/Hospital | 4 | 1 | 1 | 2019 |
| University of Utah | Academic/Hospital | 4 | 4 | 2 | 2010 |
| Kyowa Hakko Kogyo | For profit | 3 | 3 | 1 | 2016 |
| Kyowa Kirin | For profit | 3 | 3 | 1 | 2021 |
| National Institute on Drug Abuse (NIDA) | Government | 3 | 0 | 3 | 2008 |
| Ain Shams University | Academic/Hospital | 2 | 2 | 2 | 2017 |
| Biofortis | For profit | 2 | 0 | 1 | 2018 |
| Emory University | Academic/Hospital | 2 | 2 | 1 | 2022 |
| Mclean Hospital | Academic/Hospital | 2 | 2 | 1 | 2009 |
| National Institute on Aging (NIA) | Government | 2 | 0 | 1 | 2022 |
| National Institutes of Health (NIH) | Government | 2 | 1 | 2 | 2007 |
| Tanta University | Academic/Hospital | 2 | 2 | 1 | 2019 |
| University of Pavia | Academic/Hospital | 2 | 2 | 2 | 2018 |
| University of Pittsburgh | Academic/Hospital | 2 | 1 | 2 | 2007 |
| Badalona Hospital Germans Trias i Pujol | Academic/Hospital | 1 | 0 | 1 | 2006 |
| China Medical University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Clinical Institute of the Brain, Russia | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Columbia University | Academic/Hospital | 1 | 0 | 1 | 2007 |
60 organizations
Page 1 / 3